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ABSTRACT: Immunization strategies that elicit antibodies capable of neutralizing
diverse virus strains will likely be an important part of a successful vaccine against HIV.
However, strategies to promote robust humoral responses against the native intact
HIV envelope trimer structure are lacking. We recently developed chemically cross-
linked lipid nanocapsules as carriers of molecular adjuvants and encapsulated or
surface-displayed antigens, which promoted follicular helper T-cell responses and
elicited high-avidity, durable antibody responses to a candidate malaria antigen. To
apply this system to the delivery of HIV antigens, Env gp140 trimers with terminal his-
tags (gp140T-his) were anchored to the surface of lipid nanocapsules via Ni-NTA-
functionalized lipids. Initial experiments revealed that the large (409 kDa), heavily
glycosylated trimers were capable of extracting ﬂuid phase lipids from the membranes
of nanocapsules. Thus, liquid-ordered and/or gel-phase lipid compositions were
required to stably anchor trimers to the particle membranes. Trimer-loaded
nanocapsules combined with the clinically relevant adjuvant monophosphoryl lipid A primed high-titer antibody responses in
mice at antigen doses ranging from 5 μg to as low as 100 ng, whereas titers dropped more than 50-fold over the same dose range
when soluble trimer was mixed with a strong oil-in-water adjuvant comparator. Nanocapsule immunization also broadened the
number of distinct epitopes on the HIV trimer recognized by the antibody response. These results suggest that nanocapsules
displaying HIV trimers in an oriented, multivalent presentation can promote key aspects of the humoral response against Env
immunogens.
■ INTRODUCTION
HIV ranks as one of the deadliest infectious diseases among
adults and is the fourth leading cause of death worldwide.
Globally, acquired immune deﬁciency syndrome induced by
HIV infection has killed more than 25 million people (http://
www.unaids.org). UNAIDS estimates that there are about 33
million people living with HIV/AIDS worldwide, including
approximately 1.1 million people in the U.S. alone. Despite the
availability of potent antiretroviral drug regimens,1 these
staggering statistics show that the epidemic continues unabated,
underscoring the need for a potent and eﬃcacious vaccine.
Immunization strategies that elicit antibodies capable of
neutralizing diverse strains of the virus will be an important
part of a successful vaccine against HIV.
The HIV envelope glycoprotein trimer, Env, mediates virus
attachment and fusion to host cells and consists of 2 subunits
the docking portion, gp120, and the transmembrane portion
required for fusion, gp41.2,3 Env is the only neutralizing target
on the virus,4,5 but current vaccine strategies have failed to elicit
the type of durable, high avidity, broadly neutralizing humoral
responses that can confer sterilizing protection against diverse
circulating strains of HIV. Most vaccine candidates targeting
the envelope glycoprotein have used the monomer form of the
docking subunit. Such monomeric gp120 vaccines have failed to
induce broadly neutralizing antibodies in preclinical studies and
clinical trials.6 Further, antibodies elicited by monomeric gp120
bind epitopes that are poor neutralization targets and are
potentially occluded on primary HIV isolates.7,8 Several
conserved targets for antibodies against the Env proteins are
quaternary epitopes present only in the trimeric, glycosylated
native form of the envelope spike.3,8,9 Strategies to promote
durable, high avidity antibody responses against the native
intact trimer structure are lacking, and the production of stable
gp120/gp41 trimers has proven diﬃcult. However, the
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ectodomain protein, gp140, has been used as an Env surrogate,8
and use of soluble trimeric gp120 or trimeric gp140 in vaccines
has shown better promise at inducing neutralizing antibodies
relative to monomeric immunogens.8,10−15 Recently, we
described the preparation of stable and high-quality gp140
trimers (gp140T), which elicited higher titers of potent cross-
clade neutralizing antibody responses compared to correspond-
ing gp120 monomers for a diverse set of tier 1 and tier 2
viruses.8
Although soluble proteins mixed with adjuvants are most
commonly used in vaccination, delivery of antigens arrayed on
synthetic micro- and nanoparticles has shown clear advantages
over immunization with soluble immunogens in preclinical
animal models.16−18 Particulate delivery promotes antigen
uptake by antigen presenting cells (APCs), allows for
physiological display of antigens on membranes, and provides
multivalency, promoting B-cell triggering.19−22 In addition, this
approach allows for the simultaneous codelivery of antigens and
adjuvants to B-cells and APCs, which can enhance vaccine
eﬃcacy even at low antigen doses, as compared to soluble
antigens.23−27
We recently described the production of chemically cross-
linked lipid nanocapsules termed ICMVs (interbilayer-cross-
linked multilamellar vesicles) as carriers of molecular adjuvants
and encapsulated or surface-displayed antigens, which pro-
moted follicular helper T-cell responses and elicited high-
avidity, durable antibody responses to a candidate Plasmodium
vivax malaria antigen.19,23 Here, we utilize this nanocapsule
system to display membrane-anchored trimeric HIV Clade A
gp140, mimicking native viral display of the envelope
glycoprotein in a format where molecular adjuvants could be
readily coloaded in the capsule walls or entrapped in the
aqueous core. To stably anchor gp140T to the surfaces of these
particles under conditions preserving the antigenic integrity of
the trimers, we utilized noncovalent binding of polyhistidine-
tagged proteins to nitrilotri-acetic acid (NTA)-headgroup
lipids.28−30 Because NTA-Ni(II)-His binding is site speciﬁc,
the physical orientation of the protein on the nanoparticle
surface is controlled. Compositions of ICMV capsules capable
of stably anchoring the heavily glycosylated, half-megadalton
trimers were determined, and the immunogenicity of trimer-
conjugated nanocapsules compared to soluble trimers adju-
vanted with a very strong oil-in-water emulsion was determined
in mice. Importantly, nanocapsules elicited strong class-
switched antibody responses to a larger range of epitopes
with a steadily increasing avidity of trimer-binding antibody
over 90 days, which was not replicated by soluble protein
vaccines. These results suggest that nanoparticles can be
formulated to display large HIV Env trimers in an oriented,
multivalent presentation, and can promote a durable and broad
immune response against Env immunogens.
■ RESULTS AND DISCUSSION
Binding of High Molecular Weight gp140T-his to Low
Tm-Lipid Nanocapsules. Generating a durable, potent
broadly neutralizing antibody (BNAb) response is the ultimate
goal of HIV vaccines targeting humoral immunity.31,32 Potent
circulating BNAbs could potentially prevent the initial binding
of HIV to its host cell, thereby ensuring sterilizing immunity.
Early eﬀorts at development of HIV vaccines exclusively
employed monomeric forms of the envelope proteins gp120
(there is no stable monomeric form of gp41 available),33,34 but
such antigens lack quaternary epitopes found only in the
trimeric form of the envelope spike, and further expose faces of
the envelope proteins that are irrelevant to the intact native
trimer.3,9 Generation of stable trimers of Env for use as
immunogens has proven challenging, but several groups have
recently made progress in this area.8,10−15,35,36 We recently
successfully synthesized trimeric forms of the ectodomain of
gp140 from sequences obtained from an array of primary
isolates,8 enabling the testing of such an antigen for vaccination.
Initial immunization studies using soluble protein in adjuvant
suggested an ability of these trimeric proteins to elicit broader
HIV-neutralizing antibody responses compared to monomeric
gp120 proteins.8,14
Nanoparticles have been shown to enhance humoral vaccine
responses as compared to their soluble counterparts, in terms of
quantity, quality, and breadth of response.19,27,37 For lipid-
enveloped pathogens, the use of lipid-based nanoparticles
further provides the ability to mimic antigen display on the lipid
membrane of the target virus. To this end, we utilized lipid
nanocapsules we recently described, ICMVs, where the capsule
walls are composed of stacked lipid bilayers chemically
“stapled” bilayer-to-bilayer via covalent cross-links between
Figure 1. Synthesis of ICMV lipid nanocapsules loaded with HIV env trimers. (1) Anionic maleimide-functionalized liposomes, including Ni-NTA-
DGS are prepared from dried lipid ﬁlms, (2) divalent cations are added to induce fusion of liposomes and the formation of MLVs, (3) membrane-
permeable DTT is added, which cross-links maleimide lipids on apposed lipid bilayers in the vesicle walls at 37 °C, (4) post-vesicle recharging with
NiCl2, followed by addition of gp140T-his, and (5) resulting lipid particles are PEGylated with thiol-terminated PEG.
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lipid headgroups of adjacent bilayers.23 We hypothesized that
the enhanced stability of ICMVs relative to traditional
liposomes would make them more eﬀective for delivery of
surface-displayed trimer antigens, and additionally could
provide the option of incorporating high levels of molecular
adjuvants in the capsule walls or aqueous particle cores. To
provide oriented display of gp140 trimers on the surface of
these lipid nanocapsules, we took advantage of the 6 histidine
residues at the base of each “leg” of the trimer (originally
incorporated to facilitate puriﬁcation of the protein), and
utilized these to multivalently anchor gp140T to Ni-NTA-
functionalized lipids incorporated in the particle bilayers
(Figure 1). Based on our previous successful nanocapsule
vaccines carrying malaria antigens or ovalbumin23 we ﬁrst
prepared ICMVs comprising the low-Tm lipids DOPC, MPB
(maleimide-headgroup lipid for interbilayer cross-links), and
Ni-NTA-DGS (Ni-NTA-headgroup lipids for histidine-protein
capture) in a 4:5:1 mol ratio (Figure 1 step 1). Lipid capsules
were formed by fusing small unilamellar DOPC/MPB/Ni-
NTA-DGS vesicles via addition of calcium (step 2), followed by
addition of DTT as a membrane-permeable dithiol to introduce
interbilayer cross-links at 37 °C (step 3). Ni-NTA-ICMVs
containing 5% Ni-NTA-DGS were synthesized with yields
similar to DOPC/MPB-only capsules, and had a mean size of
374 ± 27 nm diameter by dynamic light scattering. To anchor
protein to the nanocapsules, ﬂuorescently tagged gp140 trimer
with histags (gp140T-his) was incubated with Ni-NTA-ICMVs
at 4 °C for 18 h (step 4), followed by a ﬁnal PEGylation step
using thiol-terminated PEG to cap any remaining maleimide
groups at the surfaces of the particles (step 5). As controls,
ICMVs loaded with his-tagged GFP were constructed in
parallel. Although ICMVs showed eﬀective binding of his-
tagged GFP, the high molecular weight trimer molecules
showed a low eﬃciency of binding to the particles at any
protein/nanocapsule ratio tested (Table 1). This low level of
binding was observed despite calculations of available NTA
groups and capsule surface area suggesting that these ∼375-nm-
diameter capsules should be capable of accommodating ∼570
trimers per particle, and therefore have a maximal capacity of
∼250 μg trimer, a 1.7-fold excess of theoretical capacity over
the total amount of trimer added. ICMVs lacking Ni-NTA lipid
showed low GFP-his binding (<5% protein binding), indicating
his-tag speciﬁcity of the protein capture by the particles. The
eﬀective binding of his-GFP conﬁrmed the functionality of Ni-
NTA groups displayed at the surfaces of ICMVs.
The eﬃciency of gp140T-his protein binding was only
modestly increased by post-insertion of additional Ni-NTA-
DGS into the capsule surfaces (Figure 2A). The low
concentration of DTT used to cross-link the lipid nanocapsule
bilayers induced some reduction of NTA-bound Ni (evidenced
by a change in color of the particle pellets from blue toward
brown), but this mild reduction did not aﬀect his-GFP binding
and recharging of nickel on the chelator groups of the particles
just prior to protein addition failed to improve trimer loading
(Figure 2A). Notably, we also found that attempting to load
trimers via an alternative noncovalent strategy, such as using an
anti-histag Ab to capture the trimers or using electrostatic
adsorption of trimers to cationic ICMVs formed with DOTAP
lipids (and thus sacriﬁcing control over protein orientation),
also failed to give yields of more than 20% of added trimer
bound to the capsules (Figure 2A).
To understand the relative failure of trimer loading we
examined the state of the histidine tags on Alexaﬂuor-labeled
gp140T-his proteins before and after attempted ICMV loading,
to rule out possible proteolytic cleavage of the anchoring
residues. Alexaﬂuor-labeled gp140T-his was added to Ni-NTA-
ICMVs and incubated for 8 h, then particles were centrifuged
and separated from the supernatant. ELISA detection of the
histidine tags on the protein was performed on the super-
natants, protein recovered from detergent-lysed ICMV
capsules, and control neat gp140T-his protein. As shown in
Figure 2B, histidines were detected on the control protein as
expected. In addition, low binding of the trimer to particles
yielded low levels of histag detection following pelleting and
lysis of the particles with Triton (DOPC-gp140T-his pellet).
Unexpectedly, however, trimer histags also failed to be detected
in the particle/trimer supernatants (∼4.42 ng/mL, Figure 2B),
despite the presence of substantial amounts of trimer protein in
these sups as detected by ﬂuorescence from the Alexaﬂuor
label. However, when imidazole, which competes with histidine
for Ni-NTA binding, was added to the supernatants, histags of
the trimer protein were again detected by ELISA (Figure 2B “+
imidazole”). This result suggested that trimer protein in the
supernatant had extracted Ni-NTA lipids from the nano-
capsules into solution, and these lipids remained bound to the
trimer and blocked access of the his-tags to detection antibodies
in the ELISA measurements.
Anchoring of gp140T-his to High-Tm Lipid Capsules.
The use of noncovalent chemical conjugation methods to
display antigen on particles has been shown previously to
enhance T-cell and antibody responses to subunit vac-
cines.29,30,38 Of note, such binding of proteins to the surface
of liposomes has typically involved proteins of substantially
lower molecular weight than the env trimer. The synthetic
gp140 trimer has a molecular weight of 409 kDa; we
hypothesized that this large molecular weight combined with
the heavy glycosylation of the protein trimer was responsible
for extraction of bound Ni-NTA lipids from the ﬂuid phase
bilayer of the capsule surfaces. In order to increase the
conjugation eﬃciency of the large trimer to the particles while
continuing to use the site-speciﬁc Ni-NTA metal chelation
method, we tested stabilizing lipid anchorage in low-Tm DOPC-
containing ICMVs by addition of cholesterol, or alternatively
exchanged DOPC for a higher Tm lipid, DMPC (Tm 23 °C). As
shown in Figure 3A, incorporation of cholesterol into DOPC
nanocapsules failed to stabilize trimer anchoring. However,
DMPC lipid nanocapsules showed a substantial increase in
gp140T-his binding, with a 9-fold increase in stable trimer
binding over DOPC capsules (Figure 3A). Following
incubation with Ni-NTA-bearing DMPC capsules, unbound
trimer protein remaining in the supernatant retained accessible
his-tags by ELISA analysis, consistent with the idea that lipid
was not being extracted from the higher-Tm lipid particles by
the trimers (Figure 3B). Despite the modest total binding
eﬃciency of 35%, this degree of protein loading translates to
approximately 160 trimers per nanocapsule, giving a mean
Table 1. Binding of GFP-his and gp140T-his to Low-Tm
Lipid ICMV Nanocapsules
HIV gp140 trimer - his GFP-his
molecular weight 408 kDaA 28 kDaA
conc. of protein added
(ug/mL)
50 75 150 150
% protein bound to
particle
6.5 ± 1.8 6.0 ± 2.7 7.3 ± 1.5 54 ± 5
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spacing between trimers on the particle surfaces of 33 nm. To
determine the stability of multivalent Ni-NTA anchoring of
trimers to the DMPC particles, we measured trimer release
from ICMVs over 7 days at 37 °C. The protein bound stably to
ICMVs and was released slowly over a period of 7 days in the
presence of 10% serum (Figure 4). Given their successful
anchoring of Env trimers, we focused on DMPC lipid
nanocapsules for subsequent in vivo immunization studies.
Humoral Response to gp140T-ICMV Vaccines. To
determine the humoral response generated by the gp140T-his
proteins displayed on ICMV lipid nanocapsules (gp140T-
ICMVs), in pilot studies we compared ICMVs to soluble
trimer. C57Bl/6 mice were immunized with various doses of
gp140T-ICMVs admixed with 5 μg of the Toll-like receptor-4
agonist MPLA, a clinically relevant molecular adjuvant.39,40
Although MPLA can be readily loaded in the membranes of the
ICMV capsules,22,23 we previously found that simply admixing
this adjuvant with ICMVs gave strong humoral responses,19
and thus we used this approach of simply admixing MPLA and
ICMVs to keep the formulations as simple as possible. For
comparison to a strong experimental adjuvant for mouse
humoral responses, soluble trimer was admixed with SAS
(Sigma Adjuvant System) adjuvant, an oil-in-water adjuvant
containing MPLA and trehalose-6,6′-dimycolate that elicits
extremely strong antibody responses in small-animal models
but is too toxic for human use. Sera were collected from
vaccinated mice over time for analysis of titer and avidity of
gp140T-speciﬁc antibodies. As shown in Figure 5A, soluble
Figure 2. HIV gp140T-his trimer binding to low-Tm lipid ICMVs. (A) Percentages of gp140T-his bound by ICMVs prepared from distinct
compositions chosen to enhance trimer loading. Various formulations to stabilize the protein on the nanoparticle vesicle (B) Accessibility of trimer
histags following incubation of gp140T-his with Ni-NTA-ICMVs was assessed by measuring the concentration of histags by ELISA.
Figure 3. HIV env trimer conjugation to ICMVs stabilized by incorporation of cholesterol or high-Tm lipids. (A) Percentage of added gp140T-his
bound to ICMVs of diﬀerent compositions. (B) Histag ELISA to determine the availability of histidine residues following attachment to high Tm
lipid vesicles.
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trimer elicited much weaker humoral responses than gp140T-
ICMVs or gp140T mixed with SAS, even when adjuvanted by
multiple TLR agonists (MPLA alone as adjuvant elicited even
weaker responses, not shown). We thus focused on comparing
ICMVs to the strong oil-in-water emulsion adjuvant. Both
soluble trimer in SAS and ICMV vaccinations were capable of
eliciting robust trimer-speciﬁc antibody responses at antigen
doses ≥1 μg (Figure 5B). However, gp140T-ICMVs appeared
to elicit a more potent response despite the use of a less
inﬂammatory adjuvant, as evidenced by readily detectable anti-
gp140T antibody after a single priming injection with 1 μg of
antigen on ICMVs (day 14) compared to no response detected
for the soluble antigen/SAS group until post-boost (day 35).
Further, ICMV vaccines at all 3 doses tested eventually
achieved essentially identical titers by 3 months post-priming,
while soluble trimer in SAS showed a 67-fold decrease in titer
as the antigen dose was reduced from 5 μg to 0.1 μg (p = 0.025,
Figure 5B). Thus, 1 μg of gp140T in SAS elicited the same IgG
titer as a 10-fold lower dose of the antigen bound to ICMVs at
3 months. Similarly, the avidity of anti-gp140T sera decayed
more quickly as a function of antigen dose for soluble trimer in
SAS compared to the nanocapsule vaccines (Figure 5C). At
higher antigen doses, both SAS and ICMVs showed similar
titers at day 90, but we did not follow these responses longer to
determine if the long-term durability of responses was
comparable.
Analysis of IgG isotypes revealed that the ICMV vaccines
elicited a more Th1/Th2-balanced humoral response, with both
IgG2c and IgG1 env-speciﬁc antibodies elicited earlier and to
higher titers at the 1 or 0.1 μg antigen doses compared to
antigen in SAS (Figure 5D, E). Thus, ICMV delivery of
oriented, membrane-bound trimers enabled strong, Th1/Th2-
Figure 4. Stability of HIV env trimer anchoring on Ni-NTA-ICMV
lipid nanocapsules. Trimer release from ICMVs over time in the
presence of medium with 10% serum at 37 °C was measured by
spectroﬂuorimetry.
Figure 5. Humoral immune responses elicited by gp140T-ICMVs. (A) C57Bl/6 mice (n = 3/group) were immunized subcutaneously at day 0 with 5
μg gp140T-his either in soluble form mixed with SAS or in soluble form mixed with MPLA (5 μg) and CpG (10 μg), or bound to ICMVs mixed
with 5 μg MPLA. Shown are total gp140-speciﬁc IgG titers at day 14. (B−E) C57Bl/6 mice (n = 3/group) were immunized subcutaneously at day 0
and day 21 with 5 μg, 1 μg, or 0.1 μg gp140T-his either in soluble form mixed with 5 μL of SAS or bound to ICMVs mixed with 5 μg of MPLA.
ELISA analysis of sera was carried out over time to assess total gp140T-speciﬁc IgG (B), avidity (C), IgG2c (D), and IgG1 (E). *, P < 0.05. All values
are reported as mean ± s.e.m.
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balanced humoral responses to be achieved at low antigen
doses where a highly inﬂammatory oil-in-water adjuvant was
ineﬀective.
Immune Sera Recognition of gp140T Epitopes
Following Nanocapsule Vaccination. We hypothesized
that presentation of HIV envelope trimers presented in a
physiological orientation on the surface of lipid nanocapsules
might promote breadth of the humoral response, by enabling a
more diverse pool of B-cells to be recruited into the immune
response via multivalent engagement of particle-bound trimers.
Following immunization, we tested the presence of binding
antibodies to several conserved linear peptide epitopes of the
trimerthe variable loops V1, V2, V3, and the conserved
Membrane-Proximal External Region (MPER). As shown in
Figure 6A−D, soluble trimer in SAS elicited responses against
the V3 peptide and these sera bound the V1 epitope at the
highest (5 μg) immunization dose, but no binding was detected
to V2 or the MPER sequence. By contrast, ICMVs elicited
responses not only against V3 and V1, but also against the V2
peptide and a weak response against the MPER segment at the
highest antigen dose (Figure 6A−D). Thus, nanocapsule
delivery of the trimer increased the breadth of responses
elicited against this key target of the humoral response against
HIV.
■ CONCLUSIONS
In conclusion, we have shown that particle display of a large,
complex HIV trimer, gp140, required the use of high-Tm lipids
to enable stable tethering to lipid nanocapsules. Importantly,
immunization with trimers anchored to ICMV lipid nano-
capsules elicited a signiﬁcantly stronger humoral response
compared to soluble protein in a strong oil-in-water emulsion
adjuvant, with a balanced production of multiple isotypes of
env-speciﬁc antibodies. Importantly, we have shown that the
use of the particulate vaccine increased the breadth of the
antibody response, as evidenced by binding antibodies
produced to several conserved targets on the envelope
structure, including the MPER seqeuence of gp41. Induction
of virus-neutralizing antibodies was not assessed here due to the
high background of mouse serum in standard neutralizing
assays, but future work will assess neutralizing titers in other
small animal models (e.g., guinea pigs). Nanoparticles can thus
be used to display large HIV trimers in an oriented, multivalent
presentation and can promote key aspects of the humoral
response against Env immunogens.
■ EXPERIMENTAL SECTION
Recombinant Gp140T-his Trimer Production. Expres-
sion of the subtype A 92UG037.8 gp140 trimer was previously
described.8,14 Brieﬂy, a stably transfected 293T cell line was
expanded to conﬂuence in DMEM supplemented with 10%
FBS and subsequently media exchanged to Freestyle 293
Figure 6. Nanocapsule-delivered trimer increases the breadth of the env-speciﬁc humoral response. ELISA analysis of sera was carried out over time
to assess titers of IgG reactive with linear peptide epitopes derived from gp140: shown are IgG responses against the V1 (A), V2 (B), and V3 (C)
loops, or the MPER (D). All values are reported as mean ± s.e.m.
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expression media (Invitrogen). Cell supernatants were collected
96 h after media exchange and subjected to standard Ni-NTA
(Qiagen) aﬃnity chromatography followed by Superose 6 (GE
Healthcare) size exclusion chromatography in 25 mM TRIS
(pH 7.5) plus 150 mM NaCl. Fractions containing the puriﬁed
protein were subjected to SDS-PAGE electrophoresis in order
to monitor purity before fractions were pooled, concentrated,
and ﬂash-frozen in liquid nitrogen and stored at −80 °C.
Synthesis of ICMVs. Interbilayer cross-linked multilamilar
vesicles (ICMVs) have been previously described.19,23 Here,
modiﬁcations were made to the procedure used by Moon et al.
to accommodate conjugation of the large molecular weight
gp140 trimers. All lipids were obtained from Avanti Polar
Lipids (Alabaster, AL) and used as received. Brieﬂy, low-Tm
lipids (1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC): 1,2-
dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)-
iminodiacetic acid)succinyl] nickel salt (Ni-NTA-DGS): 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimi-
dophenyl) butyramide] (MPB) in a 4:1:5 molar ratio), or high-
Tm lipids (1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC):Ni-NTA-DGS:MPB 4:1:5 molar ratio) in chloroform
were dried into a thin ﬁlm (total 1.26 μmol lipid) in glass vials
by evaporating the organic solvent under vacuum overnight. In
some experiments, cationic low-Tm ICMVs were prepared using
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP):-
DOPC:MPB at an 4:1:5 mol ratio. For the formation of low-
Tm ICMVs, lipid ﬁlms were rehydrated in 10 mM bis−tris
propane pH 7.0 for 1 h at 25 °C, followed by sonication at a
constant power of 5 W for 5 min on ice (Misonix Microson XL
probe tip sonicator, Farmingdale, NY). For high-Tm ICMVs,
liposome formation was carried out at a constant temperature
of 30 °C (DMPC Tm = 23 °C) with rigorous vortexing every 10
min, and then sonicated at a constant power of 5 W for 5 min
at 30 °C. Next, CaCl2 (ﬁnal conc. of 10 mM) was added to
induce fusion of the liposomes to form multilamellar vesicles
(MLV), followed by 1.5 mM DTT (maleimide/DTT molar
ratio of 2:1) and incubation of the vesicles for 1 h at 37 °C for
lipid cross-linking. The resulting ICMV lipid nanocapsules were
recovered by centrifugation at 14 000 × g for 4 min, and
washed twice with deionized water. Since DTT is known to
reduce metal ions, the ICMVs were incubated for 5 min with
100 mM NiCl2 at 25 °C to recharge the Ni-NTA groups,
followed by washing. In some of the low-Tm preparations, 5
mol % cholesterol was included to enhance bilayer stability, or
additional Ni-NTA-DGS lipids were post-inserted by incuba-
tion of ICMVs (1.26 μmol lipids) with 300 nM Ni-NTA-DGS
in PBS at 25 °C for 10 min.
In Vitro Protein Attachment and Assessment of
Trimer Stability. HIV env proteins were anchored to low-
Tm ICMV capsules by incubating Ni-NTA-bearing ICMVs
(1.26 μmol lipids) with gp140T-his (200 μg/mL) in PBS at 25
°C for 8 h. To anchor to high-Tm ICMVs, gp140T-his was
incubated with DMPC-containing ICMVs at 4 °C to ensure
binding while DMPC remained in the gel state. In some
experiments, ICMVs were loaded with GFP-his (Invitrogen,
Carlsbad, CA) as an irrelevant antigen control. Following
incubation, ICMVs were washed 3× with deionized water to
remove unbound trimer protein, then PEGylated by incubation
with 2 kDa PEG-SH (Laysan Bio, Arab, AL) in a 1.5-fold molar
excess of PEG-SH to maleimide groups for 1 h at 37 °C. The
resulting particles were washed 3× with deionized water, then
stored in PBS at 4 °C until use. As an alternative strategy for
gp140T-his protein binding, electrostatic adsorption of trimers
to cationic ICMVs formed with DOTAP lipids was also tested;
DOTAP-containing ICMVs were incubated with gp140T-his as
described above for 4 h at 25 °C, followed by washing to
remove unbound protein. As a ﬁnal alternative, the gp140T
protein was instead bound to ICMV capsules using an anti-
histag Ab (GenScript, Piscataway, NJ) anchored to the ICMV
lipids through hinge thiols: Brieﬂy, anti-histag antibody with
exposed free hinge region thiols was prepared by mixing anti-
histag (12−15 mg/mL) with a 25× molar excess of DTT for 20
min at 25 °C in the presence of 10 mM EDTA in PBS. The
mildly reduced anti-histag was passed through a desalting
column to remove DTT, and then immediately mixed with
maleimide-functionalized ICMV capsules at a ratio of 1 mg
Ab:2.5 mmol nanocapsules for covalent coupling in the
presence of 10 mM EDTA. The maleimide−thiol reaction
was allowed to proceed for at least 10 h at 25 °C, followed by
multiple washes with PBS, to remove unbound antibody.
To assess eﬃciency of gp140T-his protein attachment to the
surface of ICMVs, gp140T-his was labeled with Alexa-Fluor 647
(AF647) (Invitrogen, Carlsbad, CA) for direct ﬂuorometric
quantiﬁcation of bound protein. Release of gp140T-his labeled
with AF647 from ICMVs was quantiﬁed in PBS supplemented
with 10% fetal calf serum at 37 °C. At regular intervals,
supernatants were removed for quantiﬁcation of ﬂuorescence,
and an equal volume of fresh medium was replaced for
continued monitoring of protein release. Residual gp140T-his
remaining at the end of the time-course was determined by
disruption of the ICMV particles with 1% Triton X-100
treatment and measuring released protein by ﬂuorescence
spectrophotometry.
Anti-histag ELISA. To qualify the presence of the histidine
residue tag on gp140T-his proteins, an enzyme-linked
immunosorbent assay (Cell Biolabs, Inc., San Diego, CA)
analysis of the concentration of histags was performed on
solutions of neat AF647-labeled gp140T-his or Alexaﬂuor-
labeled protein recovered from ICMVs. Total protein
concentration was measured in parallel via AF647 ﬂuorescence,
for concurrent protein and histidine tag detection.
Vaccination Studies. Animals were cared for following
National Institutes of Health, state, and local guidelines
following an MIT IACUC-approved protocol. Groups of 6−
8-week old C57Bl/6 mice (Jackson Laboratories, Bar Harbor,
ME) were immunized subcutaneously at the tail base with the
various indicated doses of gp140T-his (either soluble form or
loaded on ICMVs) mixed with the TLR4 agonist mono-
phosphoryl lipid A (MPLA, Invivogen, San Diego, CA), or in
some cases CpG 1826 DNA (10 μg, Invivogen). As a standard,
mice were immunized with soluble gp140T-his mixed with SAS
adjuvant (Sigma, St. Louis, MO), a strong experimental
adjuvant. Mice were immunized twice, 3 weeks apart, and
anti-gp140T-his IgG titers, deﬁned as the dilution of sera at
which the 450 nm OD reading was 0.5, were determined by
ELISA analysis of sera from immunized mice. For antibody
avidity analysis, low-aﬃnity antibodies were eluted by the
addition of 6 M urea for 10 min at 25 °C following serum
incubation. The antibody titers (450 nm OD reading) obtained
with and without addition of urea were then used to calculate
the IgG avidity values.
Statistics. Statistical analysis was performed with Graphpad
Prism (La Jolla, CA). Data sets were analyzed using one-way
analysis of variance (ANOVA). p-Values less than 0.05 were
considered statistically signiﬁcant. All values are reported as
mean ± s.e.m.
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